Koblenz, Saskatchewan – [2024.09.16] – ADREXpharma, a leading pharmaceutical company renowned for its expertise in the development, distribution, and marketing of medical cannabis, and Mother Labs, a premier IP and genetics company from Canada, are thrilled to announce their exclusive strategic partnership. Together, they will introduce a premium line of cannabis flower brands to the German medical market under the “Mother Labs” name, delivering unparalleled quality and innovation to medical patients.
This collaboration combines ADREXpharma’s extensive experience in pharmaceutical distribution, regulatory affairs, and market dynamics with Mother Labs’ cutting-edge genetic development and breeding capabilities. “This partnership represents a significant milestone in our mission to provide German medical patients with the highest quality cannabis products,” said Nicole Broockmann CEO of ADREXpharma. “Mother Labs’ advanced genetic development capabilities perfectly complement our distribution and regulatory expertise. Together, we will bring a product to market that meets the highest standards of quality and consistency.”
Mother Labs, known for its innovative approach to cannabis breeding, excels in creating distinct cannabis cultivars tailored to consumer preferences. “We are excited to bring our advanced genetics to Germany in partnership with ADREXpharma,” said Brian Bain, CEO of Mother Labs. “Our purpose-built facility, with dedicated pheno-hunting space and comprehensive storage via our TC lab, allows us to rigorously test all genetics in-house for a minimum of 72 weeks before release. This precision process ensures that only the highest quality, stable, and unique genetics make it to market, reinforcing our position as leaders in genetic innovation.”
Since cannabis legalization in 2019, Mother Labs has worked with many of the top Canadian producers, supplying the market with over 150 different genetics. The company has also established a strong presence in international markets, including the UK, Australia, and South Africa. Their continuous testing and expanding genetic resources drive innovation, making this partnership with ADREXpharma a significant step in bringing world-class flower products to the Germany’s medical market.
The new “Mother Labs” branded flower line will initially launch with a selection of premium cannabis flowers, specifically designed to meet the needs of medical patients, and will be available through pharmacies across Germany.
ADREXpharma and Mother Labs are committed to maintaining the highest standards of compliance, quality control, and customer satisfaction as they expand their presence in the European market.
For more information or investment inquiries, please contact:
ADREXpharma GmbH
Nicole Broockmann
[email protected]
www.adrexpharma.com]
Mother Labs
Brian Bain, CEO
[email protected]
Jeff Bourassa, Investment Contact
[email protected]
www.motherlabs.ca
